Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where David G. Bostwick is active.

Publication


Featured researches published by David G. Bostwick.


Cancer | 2001

Risk of prostate carcinoma death in patients with lymph node metastasis

Liang Cheng; Horst Zincke; Michael L. Blute; Erik J. Bergstralh; Beth Scherer; David G. Bostwick

The presence of lymph node metastasis is a poor prognostic sign for patients with prostate carcinoma. Results of published reports on survival among patients with lymph node metastasis are difficult to assess because of treatment selections. The extent to which lymph node status will have an impact on a patients survival is uncertain.


Cancer | 1998

Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma

David G. Bostwick; Anna Pacelli; Michael Blute; Patrick C. Roche; Gerald P. Murphy

Prostate specific membrane antigen (PSM) is a membrane‐bound antigen that is highly specific for benign and malignant prostate epithelial cells. Its expression in high grade prostatic intraepithelial neoplasia (PIN) has not been compared with that in prostate carcinoma.


Cancer | 1997

Artificial neural networks improve the accuracy of cancer survival prediction

Harry B. Burke; Philip H. Goodman; David B. Rosen; Donald E. Henson; John N. Weinstein M.D.; Frank E. Harrell; Jeffrey R. Marks; David P. Winchester; David G. Bostwick

The TNM staging system originated as a response to the need for an accurate, consistent, universal cancer outcome prediction system. Since the TNM staging system was introduced in the 1950s, new prognostic factors have been identified and new methods for integrating prognostic factors have been developed. This study compares the prediction accuracy of the TNM staging system with that of artificial neural network statistical models.


Cancer | 1999

Correlation of margin status and extraprostatic extension with progression of prostate carcinoma

Liang Cheng; Michael F. Darson; Erik J. Bergstralh; Jeff Slezak; Robert P. Myers; David G. Bostwick

The correlation of surgical margins and extraprostatic extension (EPE) with progression is uncertain with regard to prostate carcinoma patients treated by radical prostatectomy. The objective of this study was to define factors predictive of cancer progression; emphasis was placed on surgical margins and their relation to extraprostatic extension.


Cancer | 1995

High grade prostatic intraepithelial neoplasia. The most likely precursor of prostate cancer

David G. Bostwick

The search for the precursor of prostatic adenocarcinoma has focused in recent years on the spectrum of histopathologic changes referred to as high grade prostatic intraepithelial neoplasia (PIN). This review describes the diagnostic criteria and clinical significance of PIN.


Cancer | 1998

Independent origin of multiple foci of prostatic intraepithelial neoplasia: Comparison with matched foci of prostate carcinoma

David G. Bostwick; Ailin Shan; Junqi Qian; Micheal Darson; Nita J. Maihle; Robert B. Jenkins; Liang Cheng

Prostate carcinoma usually is heterogeneous and multifocal, with diverse clinical and morphologic manifestations. Understanding of the molecular basis for this heterogeneity is limited, particularly for the putative precursor, high grade prostatic intraepithelial neoplasia (PIN). In this study, the authors attempted to determine the genetic relation between multiple foci of PIN and matched foci of carcinoma, and whether they are independent in origin.


Cancer | 1992

The association of benign prostatic hyperplasia and cancer of the prostate

David G. Bostwick; William H. Cooner; Louis Denis; George W. Jones; Peter T. Scardino; Gerald P. Murphy

There are a number of similarities between benign prostatic hyperplasia (BPH) and cancer. Both display a parallel increase in prevalence with patient age according to autopsy studies (86.2% and 43.6%, respectively, by the ninth decade), although cancer lags by 15–20 years. Both require androgens for growth and development, and both respond to antiandrogen treatment regimens. Most cancers arise in prostates with concomitant BPH (83.3%), and cancer is found incidentally in a significant number of transurethral prostatectomy (TURP) specimens (10%). The clinical incidence of cancer arising in patients with surgically treated BPH is approximately 3%. BPH may be related to a subset of prostate cancer which arises in the transition zone, perhaps in association with atypical adenomatous hyperplasia (AAH). It is important to exclude cancer in patients presenting with symptoms of bladder outlet obstruction presumably due to BPH. For such patients, we recommend digital rectal examination (DRE) and, at least in high‐risk patients, serum prostate specific antigen (PSA) determination. Transrectal ultrasound (TRUS) should be employed in patients with elevated PSA levels to determine the volume of the prostate, the relative contribution of BPH to volume, and the PSA density (ratio of PSA level to volume). Biopsy should be obtained from any area suspicious for cancer. Early detection and treatment of cancer when it is localized offers the greatest chance for cure.


Cancer | 1999

The radial distance of extraprostatic extension of prostate carcinoma : Implications for prostate brachytherapy

Brian J. Davis; Thomas M. Pisansky; Torrence M. Wilson; Harold J. Rothenberg; Anna Pacelli; David W. Hillman; Daniel J. Sargent; David G. Bostwick

Extraprostatic extension (EPE) is an unfavorable prognostic factor in patients with prostate carcinoma. Prior studies have reported the linear extent of EPE measured circumferentially along the edge of the prostate. In this study, the authors defined and evaluated a novel measure of EPE in a large series of radical prostatectomy specimens. These results have important clinical implications in the management of localized prostate carcinoma by brachytherapy and other modalities.


Cancer | 1996

Prospective origins of prostate carcinoma: Prostatic intraepithelial neoplasia and atypical adenomatous hyperplasia

David G. Bostwick

The search for the precursor of prostatic adenocarcinoma has focused in recent years on two histopathologic findings: high grade prostatic intraepithelial neoplasia (PIN) and atypical adenomatous hyperplasia (AAH). This article describes the diagnostic criteria and clinical significance of PIN and AAH. METHODS AND RESULTS. PIN is the most likely precursor of prostate carcinoma. The continuum that culminates in high grade PIN and early invasive carcinoma is characterized by progressive basal cell layer disruption, loss of markers of secretory differentiation, nuclear and nucleolar abnormalities, increasing proliferative potential, increasing microvessel density, variation in DNA content, and allelic loss. Clinical studies suggest that PIN predates carcinoma by 10 years or more, with low grade PIN first appearing in men in their 30s. AAH is usually found in the transition zone, and shows a weak and inconclusive link to well differentiated adenocarcinoma of the transition zone. CONCLUSIONS. The significance of recognizing PIN is based on its strong association with prostatic carcinoma. PIN coexists with carcinoma in most cases, but retains an intact or fragmented basal cell layer, unlike carcinoma, which lacks a basal cell layer. High grade PIN in biopsies predicts the presence of carcinoma in subsequent biopsies, and PIN provides the highest risk ratio of all known predictive factors. This finding indicates the need for repeat biopsy and follow‐up when PIN is identified in a biopsy, especially in patients with an elevated serum prostate specific antigen concentration. PIN also offers promise as an intermediate endpoint in studies of chemoprevention of prostatic carcinoma. Unlike PIN, AAH is weakly linked to carcinoma, and current data indicate that no follow‐up is necessary for patients with this finding. Cancer 1996;78:330‐6.


Cancer | 2000

Predicting the survival of bladder carcinoma patients treated with radical cystectomy

Liang Cheng; Amy L. Weaver; Bradley C. Leibovich; Dharamdas M. Ramnani; M R N Roxann Neumann; Beth G. Scherer; Ajay Nehra; Horst Zincke; David G. Bostwick

Clinical outcomes vary for patients treated with radical cystectomy. The authors sought to identify factors associated with the survival of patients treated with radical cystectomy for urothelial carcinoma of the urinary bladder.

Collaboration


Dive into the David G. Bostwick's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge